Company Details

Focus	ONCOLOGY
Partnership	Akeso Inc.
Summit License Territories	United States, Canada, Europe, Japan
Chief Executive Officers	Bob Duggan Chairman & CEO Dr. Maky Zanganeh CEO & President
NASDAQ	SMMT
Market Cap	$1.83B*
Employees	111†
Offices	Miami, FL Menlo Park, CA Oxford, UK

*As of Dec 31, 2023 †As of January 8, 2024

Committed to Optimizing Human Health

Summit Therapeutics is committed to leadership in resolving serious, unmet medical needs for the betterment of overall human health. Summit's mission is to improve quality of life, increase potential duration of life, and resolve serious medical unmet need. Summit's leadership has unmatched high-speed execution and a proven track record in oncology, ***focused on patients first.***

Strategic Global Partnership

With an aligned mission - Bringing ivonescimab to patients in need.

Summit Therapeutics, Inc. has partnered with Akeso Inc. (HKEX Code: 9926.HK, "Akeso"), to in-license the novel, innovative bispecific antibody, ivonescimab. Akeso is a pioneer and source originator in developing innovative antibodies.

Ivonescimab

Ivonescimab, known as SMT112 in Summit's license territories, and as AK112 in China and Australia, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Currently, over 1,000 patients have been treated with ivonescimab around the world across 19+ oncology clinical trials to date.

Lead Compound: Ivonescimab

Only Phase III PD-1/VEGF Bispecific Antibody in Summit License Territories*



Designed to Optimize the Balance of Anti-tumor Activity & Safety[1,2]

- **First-in-Class* PD-1/VEGF bispecific antibody** that brings two validated oncologic mechanisms[3,4,5] into ONE novel tetravalent molecule
- **Cooperative Binding:** Simultaneous blocking of PD-1 & VEGF[1,3,6] designed to provide increased avidity in the TME[7] and increased activity of T Cells[7,8] as shown *in vitro*
- **Potential to steer to tumor vs. healthy tissue** where there are higher levels of PD-1 & VEGF[1,2,7,8]
- **Only Phase III PD-1/VEGF bispecific in clinical development** in North America, Europe & Japan*

Ivonescimab is an investigational therapy that is not approved by any regulatory authority. Ivonescimab is currently being investigated in Global Phase III clinical studies.

*There are no known PD-1-based bispecific antibodies approved by the U.S. Food and Drug Administration ("FDA") or the European Medicines Agency ("EMA").

1. Zhao Y, et al. eClinicalMedicine. 2023; 3(62): 102106; **2.** Zhou C, et al. J Clin Oncol. 2022;40:16_suppl, 9040; **3.** Manegold C, et al. J Thorac Oncol 2017;12(2):194-207; **4.** Pardoll, D. Nat Rev Cancer 2012;12(4):252-64; **5.** Tamura R, et al. Med Oncol 2020;37(1):2; **6.** Data on File. [14, 15] Summit Therapeutics Inc.; **7.** Zhong T, et al. AACR-NCI-EORTC International Conference 2023.Poster #B123, Abstract #35333, Boston, MA, USA; **8.** Zhong T, et al. JITC 2022;10(2):521

SUMMIT THERAPEUTICS

Ivonescimab Mechanism of Action

Cooperative Binding

Simultaneous blocking of PD-1 & VEGF[1,2,3]

Increased Avidity in TME*

VEGF increases affinity to **PD-1 by >18X**[4]
PD-1 increases affinity to **VEGF by >4X**[4]
(as shown *in vitro*)

Enhanced Activity of T Cells

VEGF dimer leads to potential interconnection of ivonescimab molecules, which may increase activity of T cells[4,5]



*TME: Tumor Microenvironment

1. Zhao Y. et al., eClinicalMedicine. 2023; 3(62): 102106., **2.** Manegold C, et al. J Thorac Oncol 2017;12(2):194-207 **3.** Data on File. [14, 15] Summit Therapeutics Inc.
4. Zhong T, et al. AACR-NCI-EORTC International Conference 2023.Poster #B123,Abstract #35333, Boston, MA, USA, **5.** Zhong T, et al. JITC 2022;10(2):521.

Ivonescimab Global Oncology Clinical Trials

1,000+ Patients Treated with Ivonescimab Across 19 Clinical Trials

Summit therapeutics

	Trial	Indication	Histology/Population	Regimen	Phase III
★	HARMONi	NSCLC	**EGFRm+** 2L+ Advanced or Metastatic	Combo ivonescimab + chemo vs. placebo + chemo	
★	HARMONi-3	NSCLC	**Squamous** 1L Metastatic	Combo ivonescimab + chemo vs. pembro + chemo	

Akesobio

These ivonescimab clinical trials are being conducted in China and/or Australia and are fully sponsored and managed by Akeso.

	Indication	Regimen	Phase I	Phase II	Phase III
★	NSCLC: 2L EGFRm+	Randomized: Combo (chemo) vs. chemo			
	NSCLC: 1L PD-L1 TPS>1%	Randomized: Monotherapy vs. pembro (PD-1)			
★	NSCLC: 1L Squamous	Randomized: Combo (chemo) vs. tislelizumab (PD-1) + chemo			
	NSCLC: 1L Squamous	Randomized: Combo (chemo) vs. pembro (PD-1) + chemo			
	Advanced Solid Tumors	Monotherapy			
	NSCLC	Combo (chemo)			
	NSCLC	Monotherapy			
	GYN Tumors	Monotherapy			
	Ovarian Cancer	Combination (PARPi)			
	NSCLC	Monotherapy & Combo (chemo)			
	CRC	Combo (CD47 + chemo)			
	HCC	Monotherapy			
	NSCLC	Combo (PD-1 / CTLA-4 bsAb + chemo)			
	HNSCC	Combo (CD47)			
	Advanced Solid Tumors**	Combo (CD47, CD47 + chemo, chemo)			
	TNBC	Comb (chemo, CD47 + chemo)			
	NSCLC	Combo (CD73 + chemo)			
	Advanced Solid Tumors	Monotherapy			
	ES-SCLC	Combo (chemo)			

★ Same Subset Patient Population

★ Same Subset Patient Population

Ivonescimab is currently being investigated in Global Phase III clinical studies. Phase I and II have been completed by our partner Akeso. This pipeline reflects studies that have been announced.

NSCLC: Non-Small-cell Lung Cancer, EGFRm+: Epidermal Growth Factor Receptor mutant positives, Combo: Combination, Chemo: Chemotherapy, pembro: pembrolizumab, CRC: Colorectal Cancer, HCC: Hepatocellular Carcinoma, HNSCC: Head & Neck Squamous Cell Carcinoma, BTC: Biliary Tract Cancer, TNBC: Triple Negative Breast Cancer, ES-SCLC: Extensive Stage Small Cell Lung Cancer, PD-1: Programmed Cell Death Protein 1, PARPi: poly(ADP-ribose) polymerase inhibitors

smmttx.com **investors@smmttx.com**

Summit therapeutics